Analyst Matthew Caufield of H.C. Wainwright reiterated a Buy rating on Unity Biotechnology (UBX – Research Report), with a price target of $8.00.
Matthew Caufield has given his Buy rating due to a combination of factors surrounding Unity Biotechnology’s promising developments in treating diabetic macular edema (DME). The upcoming Phase 2B ASPIRE trial results, expected in the first quarter of 2025, are anticipated to be a pivotal moment for their lead therapy, foselutoclax (UBX1325). This trial is significant as it compares foselutoclax directly with the current industry standard treatment, aflibercept, potentially showcasing a novel mechanism of action that targets senescent cells in the retina.
The previous Phase 2 BEHOLD trial demonstrated promising long-term benefits, such as improved vision and reduced retinal thickness, without the need for additional anti-VEGF treatments. These results suggest that foselutoclax could offer a differentiated and durable benefit for DME patients. With the stock trading slightly above cash and the potential for pivotal development on the horizon, Caufield reiterates a Buy rating and maintains an $8 price target, reflecting optimism about the therapy’s future impact and market potential.
Questions or Comments about the article? Write to editor@tipranks.com